​

Collaboration drives discovery. Dr. Jens Carlsson shows how cross-disciplinary teamwork turns GPCR models into real translational outcomes.

Dr. Jens Carlsson reveals how predictive modeling is reshaping GPCR drug discovery—bridging computation, chemistry, and pharmacology for real-world impact.

Nine out of ten GPCR programs stall not because the target was wrong, but because teams waited too long to test the right thing. Terry Kenakin has seen this story play out for 40 years — and he’s rewriting the ending.

Can GPCR models predict biology? Dr. Jens Carlsson shares how structure-based modeling is transforming drug discovery, and why collaboration is key.

The next edge in discovery isn’t louder exposure—it’s smarter engagement. This week’s Dr. Kenakin from Terry's Corner shows how to tame irreversible drugs so their kinetic power works for you, not against you. You’ll get a framework to predict duration, penetration, and PK/PD separation—so decisions move faster and risks surface earlier. Breakthroughs this week: nanomedicines targeting PAR2 for sustained analgesia; Emerging Voices in GPCR Biology;